Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
EMA
breast cancer
drugs approval
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
08
09
2021
revised:
07
10
2021
accepted:
10
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.
Identifiants
pubmed: 34680350
pii: cancers13205198
doi: 10.3390/cancers13205198
pmc: PMC8533780
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Lancet. 2017 Dec 17;388(10063):2997-3005
pubmed: 27908454
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
Ann Oncol. 2021 Aug;32(8):1015-1024
pubmed: 34102253
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Eur J Cancer. 2018 Jan;89:27-35
pubmed: 29223479
JAMA Oncol. 2020 Jan 1;6(1):116-124
pubmed: 31563959
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
J Clin Oncol. 2021 May 1;39(13):1448-1457
pubmed: 33539215
Ann Oncol. 2021 Aug;32(8):983-993
pubmed: 34272041
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Lancet Oncol. 2021 Jan;22(1):85-97
pubmed: 33357420
Clin Breast Cancer. 2021 Feb;21(1):80-91.e7
pubmed: 33183970
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882